1.New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.
Frontiers of Medicine 2022;16(1):17-24
Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism. GLP-1 can also delay stomach emptying and suppress appetite to help lose weight. This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.
Diabetes Mellitus, Type 2/drug therapy*
;
Glucagon-Like Peptide-1 Receptor/therapeutic use*
;
Glucagon-Like Peptides
;
Humans
;
Hypoglycemic Agents/therapeutic use*
;
Motivation
;
Obesity/drug therapy*
2.Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease.
Xiao-Hui WANG ; Wei YANG ; Jin-Shun QI
Acta Physiologica Sinica 2010;62(5):398-406
There is a close correlation between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) in the course of pathophysiological processes. The neuroprotective action of glucagon-like peptide 1 (GLP-1), a latest drug for clinical treatment of T2DM, is being more deeply investigated at present, and a novel therapeutic strategy for AD with GLP-1 has been proposed boldly. This review mainly discussed the correlation of pathogenesis between T2DM and AD, the synthesis and secretion of GLP-1, the distribution and physiological effects of GLP-1 receptor in the brain, and the progresses on the study of GLP-1 in the treatment of AD.
Alzheimer Disease
;
drug therapy
;
physiopathology
;
Amyloid beta-Peptides
;
drug effects
;
metabolism
;
Animals
;
Brain
;
metabolism
;
Diabetes Mellitus, Type 2
;
physiopathology
;
Glucagon-Like Peptide 1
;
pharmacology
;
therapeutic use
;
Glucagon-Like Peptide-1 Receptor
;
Humans
;
Neuroprotective Agents
;
pharmacology
;
therapeutic use
;
Receptors, Glucagon
;
metabolism
3.Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07.
Jing HAN ; Li-Dan SUN ; Hai QIAN ; Wen-Long HUANG
Chinese Journal of Natural Medicines (English Ed.) 2014;12(8):613-618
AIM:
To identify the glucose lowering ability and chronic treatment effects of a novel coumarin-glucagon-like peptide-1 (GLP-1) conjugate HJ07.
METHOD:
A receptor activation experiment was performed in HEK 293 cells and the glucose lowering ability was evaluated with hypoglycemic duration and glucose stabilizing tests. Chronic treatment was performed by daily injection of exendin-4, saline, and HJ07. Body weight and HbA1c were measured every week, and an intraperitoneal glucose tolerance test was performed before treatment and after treatment.
RESULTS:
HJ07 showed well-preserved receptor activation efficacy. The hypoglycemic duration test showed that HJ07 possessed a long-acting, glucose-lowering effect and the glucose stabilizing test showed that the antihyperglycemic activity of HJ07 was still evident at a predetermined time (12 h) prior to the glucose challenge (0 h). The long time glucose-lowering effect of HJ07 was better than native GLP-1 and exendin-4. Furthermore, once daily injection of HJ07 to db/db mice achieved long-term beneficial effects on HbA1c lowering and glucose tolerance.
CONCLUSION
The biological activity results of HJ07 suggest that HJ07 is a potential long-acting agent for the treatment of type 2 diabetes.
Animals
;
Blood Glucose
;
metabolism
;
Coumarins
;
pharmacology
;
Diabetes Mellitus
;
blood
;
drug therapy
;
Diabetes Mellitus, Type 2
;
drug therapy
;
Exenatide
;
Glucagon-Like Peptide 1
;
analogs & derivatives
;
pharmacology
;
therapeutic use
;
Glucagon-Like Peptide-1 Receptor
;
Glucose Tolerance Test
;
Glycated Hemoglobin A
;
metabolism
;
HEK293 Cells
;
Humans
;
Hypoglycemic Agents
;
pharmacology
;
therapeutic use
;
Male
;
Mice, Inbred C57BL
;
Mice, Knockout
;
Peptides
;
pharmacology
;
Receptors, Glucagon
;
metabolism
;
Venoms
;
pharmacology